The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Narrator Verle was lucky. Out of 100 Emory Eye Center applicants, he was one of five chosen for a clinical trial of Lucentis, a new drug just approved by the FDA to treat the wet form of the disease.

Twelve NHS bodies in the north east of England were offering these patients Avastin, a cheaper alternative to the licensed drug, Lucentis. David Hambleton, chief executive officer of NHS South ...

Bs: Bevasiranib sodium; CABERNET: A study of Strontium 90 β Radiation With Lucentis to Treat Age-Related Macular Degeneration; CARBON: Combination of Bevasiranib and Lucentis Therapy in Wet AMD ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...